With a one year PEG ratio of 0.24, Health Catalyst Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.81% of US stocks.
Health Catalyst Inc's stock had its IPO on July 25, 2019, making it an older stock than just 0.09% of US equities in our set.
HCAT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.45% of US stocks.
If you're looking for stocks that are quantitatively similar to Health Catalyst Inc, a group of peers worth examining would be AERI, ARLO, DMRC, ORGS, and PSTG.
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services. The company is headquartered in Salt Lake City, Utah.
Health Catalyst (HCAT) has agreed to acquire healthcare IT shop healthfinch for an undisclosed sum in cash and stock.Madison, WI-based healthfinch has developed a workflow integration engine that, it says, delivers insights and analytics into electronic medical record ((EMR)) workflows that automate doctors' ability to close patient care gaps in...
SALT LAKE CITY, July 1, 2020 /PRNewswire/ -- Today, Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, announced the launch of its Care Management Suite, a patient-centric data- and…
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
Today, Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, announced its participation in the COVID-19 Evidence Accelerator, an expansive public-private partnership that combines the efforts of academic, government, and private sector organizations by applying real-world data to advance the understanding of COVID-19. The COVID-19 Evidence Accelerator was launched by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research (Friends).